1. Home
  2. APRE vs WATT Comparison

APRE vs WATT Comparison

Compare APRE & WATT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • APRE
  • WATT
  • Stock Information
  • Founded
  • APRE 2006
  • WATT 2012
  • Country
  • APRE United States
  • WATT United States
  • Employees
  • APRE N/A
  • WATT N/A
  • Industry
  • APRE Biotechnology: Biological Products (No Diagnostic Substances)
  • WATT Radio And Television Broadcasting And Communications Equipment
  • Sector
  • APRE Health Care
  • WATT Technology
  • Exchange
  • APRE Nasdaq
  • WATT Nasdaq
  • Market Cap
  • APRE 10.0M
  • WATT 9.3M
  • IPO Year
  • APRE 2019
  • WATT 2014
  • Fundamental
  • Price
  • APRE $1.89
  • WATT $0.49
  • Analyst Decision
  • APRE Strong Buy
  • WATT
  • Analyst Count
  • APRE 2
  • WATT 0
  • Target Price
  • APRE $15.50
  • WATT N/A
  • AVG Volume (30 Days)
  • APRE 50.1K
  • WATT 2.2M
  • Earning Date
  • APRE 08-11-2025
  • WATT 08-07-2025
  • Dividend Yield
  • APRE N/A
  • WATT N/A
  • EPS Growth
  • APRE N/A
  • WATT N/A
  • EPS
  • APRE N/A
  • WATT N/A
  • Revenue
  • APRE $1,284,475.00
  • WATT $1,047,000.00
  • Revenue This Year
  • APRE N/A
  • WATT $1,028.91
  • Revenue Next Year
  • APRE N/A
  • WATT N/A
  • P/E Ratio
  • APRE N/A
  • WATT N/A
  • Revenue Growth
  • APRE 33.27
  • WATT 137.41
  • 52 Week Low
  • APRE $1.41
  • WATT $0.12
  • 52 Week High
  • APRE $5.01
  • WATT $2.70
  • Technical
  • Relative Strength Index (RSI)
  • APRE 55.82
  • WATT 66.17
  • Support Level
  • APRE $1.60
  • WATT $0.42
  • Resistance Level
  • APRE $2.22
  • WATT $0.61
  • Average True Range (ATR)
  • APRE 0.17
  • WATT 0.07
  • MACD
  • APRE 0.03
  • WATT 0.01
  • Stochastic Oscillator
  • APRE 46.77
  • WATT 62.89

About APRE Aprea Therapeutics Inc. Common stock

Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline products include ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.

About WATT Energous Corporation

Energous Corp has developed wireless power networks technology (WPNT), consisting of semiconductor chipsets, software controls, hardware designs, and antennas, that enable radio frequency (RF) based charging for Internet of Things (IoT) devices. The WPN technology provides a comprehensive suite of capabilities designed to power the next generation of wireless energy networks, seamlessly delivering power and data across diverse, battery-free device ecosystems. It enhances operational visibility, control, and intelligent business automation. Its products include Transmitter IC & Module, Receivers IC, Transmitter System, and Evaluation Kits.

Share on Social Networks: